Spectrum Pharmaceuticals, Inc.
Combination therapy using belinostat and pralatrexate to treat lymphoma

Last updated:

Abstract:

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.

Status:
Grant
Type:

Utility

Filling date:

14 Jun 2016

Issue date:

13 Sep 2022